Pretargeted Radioimmunotherapy of Pancreatic Cancer Xenografts: TF10–⁹⁰Y-IMP-288 Alone and Combined with Gemcitabine

Abstract

PAM4-based PT-RAIT with (90)Y hapten peptide is an effective treatment for pancreatic cancer, with less toxicity than (90)Y-PAM4 IgG, in this model. Combinations with gemcitabine and dose fractionation of the PT-RAIT enhanced therapeutic responses.